Placebomics: Where placebo and genetics meet

Last Updated on

December 01, 2017 – The placebome is a new game in town. That is where genetics and the placebo effect meet. The underlying discipline of study may well be “placebomics”, fitting genetics and the uniquely complex phenotype “Placebo Effect” into the -omics age of things. In fact, with the advent of genomics, researchers are learning that placebo responses are modified by a person’s genetics. In 2015, a review article explored the many questions that this raises regarding the role of the placebo in both patient care and in drug development.

Placebo has helped to ease symptoms of illness for centuries and have been a fundamental component of clinical research to test new drug therapies for more than 70 years. But why some people respond to placebos and others do not remains under debate. Genetic sequencing is revealing that the placebo response is, in fact, a complex phenotype with an unfolding physiology; the study of genomic effects on the placebo response, what some authors call “the placebome“, is in its infancy, but there is already ample evidence that genetic variations in the brain’s neurotransmitter pathways modify placebo effects. As a result, placebo responses are emerging as a legitimate series of molecular and biological reactions, most likely organized in complex (neurological) networks of interacting genes (and their respective coded for proteins) in the placebome (see the mind boggling 2017 article by Wang et al. in the Journal of Clinical Investigation for an overview).

The exciting question is now if there exist definitive genetic biomarlers which could be used to prospectively identify individuals who are perceptive for placebo responses? If so, how many of such genetic biomarkers exist? Can the medical field harness the placebo response to enhance personalized medical treatment? What might be the impact of placebo-drug interactions? And what will this new information mean for randomized clinical trials, which depend on

The placebome module.

placebo controls to test the efficacy of new drug candidates? Should a “no-treatment” control be added to future trials?

In 2012, a first genetic placebo biomarker, the catechol-O-methyltransferase (COMT) gene, was identified in that a genetic variation (in particular the exonic SNP (rs4680, Val158Met)) in COMT, which influences the brain’s levels of the neurotransmitter dopamine, also determined the extent of an individual’s placebo response in irritable bowl syndrome (IBS).

While traditionally scientists used behavioral instruments, such as personality measures, to predict which patients would respond to placebo, the development of sophisticated neuroimaging technologies over the last couple of years illuminated the activation of the brain’s neurotransmitter pathways in response to placebo. Because the regulation of these pathways (including dopamine, opioid, endocannabinoid and serotonin pathways) govern the chemical messengers (neurotransmitters) that either excite or inhibit nerve function in the brain, many neurotransmitters play key roles in reward and pain. It comes then as no surprise that genetic variation in the genes that encode the proteins in these neurotransmitter pathways might also modify placebo responses, the allelic variant Val158Met of COMT being a first example.

The article by Wang et al. (see above) further explores the concept of the placebome and puts it into relation to similar gene networks thought to be active in drug action (drug modules) and in disease aetiologies and responses to treatment (disease modules). Within this framework, the researchers hope to further decipher the physiological basis of placebo and to find the raisons for differences of the strength of placebo in diseases where this effect is high (such as  alcoholism, anxiety, asthma, Crohn’s disease, depression, diabetic neuropathies, duodenal ulcer, epilepsy, eating disorders, fibromyalgia, irritable bowel syndrome, Parkinson disease, migraine disorders, osteoarthritis, chronic pancreatitis, restless leg syndrome, schizophrenia, and ulcerative colitis) versus diseases where this effect is low or absent (such as bacterial infection, infertility, viremia, pneumothorax, uremia, hepatocellular carcinoma and renal cell carcinoma. There have been about 15 candidate genes identified which may be implicated at the origin of the placebo effect; further research will more clearly reveal their role, the involvement of particular mutations, and eventually allow to identify individuals, based on genetic tests, who are naturally carrying a strong placebo effect predispostion (giving rise to the field of placebomics).

Possibility of “Placebo-Drug Interactions” and “No-Treatment Arms” in Clinical Trials

Knowing that neurotransmitter pathways are involved in placebo responses now raises a new consideration for both patient care and clinical research. Since seemingly neurotransmitter pathways are modified by genetics and are pathways that both drugs and the placebo act on,  drugs could change a placebo response and a placebo response could modify a drug response. This potential overlap between placebo, drug treatment and disease adds to the complexity of the placebome and underscores the importance of understanding how it fits into larger more complex networks.

The possibility that there could be a placebo-drug interaction as a result of genetic variation in placebo pathway genes suggests that one needs to refine and recalibrate the assumptions of placebo controls in randomized clinical trials. An important next step in describing the placebome would be to include a no-treatment control in placebo-controlled randomized clinical trials. This approach might be cost effective and allow for a broad view of placebo response genes and other molecules across varying conditions and treatments.

It may no longer be sufficient for pharmaceutical research to include in randomized clinical trials a “placebo arm,” which is designed to control for the non-specific, non-pharmacological effects that are part of the administration and receipt of clinical treatment. In order to properly study the placebo response,  a frank “no -treatment” control may have to be incorporated into well designed future clinical trials. This may help to provide the right treatment in the right place at the right time, not only for the responding patient, but also for the “placebo patient”.

Note that Thasso Post had in the past articles on placebo entitled *Outssmarting the placebo effect” (here) and “Pain: Placebo’s sweet hot spot in the brain identified” (here).



Tags: , , , , , , , , , , ,
About the Author
Joseph Gut - thasso Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.
1 Pings/Trackbacks for "Placebomics: Where placebo and genetics meet"

Your opinion


No comments yet

thasso: conditions

thasso: newest tweets

thasso: recent comments

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Findings in mice reveal possibilities for fetal drug therapy for deafness April 6, 2020
    New research led by hearing scientists at Oregon Health & Science University suggests an avenue to treat and prevent intractable genetic disorders before birth.
  • Study of rare genetic disorder that effects the eyes April 3, 2020
    Nagano prefecture is home to a group of people affected with a rare genetic neurodegenerative disorder called familial amyloid polyneuropathies (FAP). This disease impacts the gene encoding protein transthyretin (TTR) which is produced in the liver and also eyes. Liver transplants are often a treatment for this disease, but severe eyesight problems such as cloudiness […]
  • Natural sunscreen gene influences how we make vitamin D April 2, 2020
    Genetic variations in the skin can create a natural sunscreen, according to University of Queensland researchers investigating the genes linked with vitamin D.
  • Single mutation leads to big effects in autism-related gene April 2, 2020
    A new study in Neuron offers clues to why autism spectrum disorder (ASD) is more common in boys than in girls. National Institutes of Health scientists found that a single amino acid change in the NLGN4 gene, which has been linked to autism symptoms, may drive this difference in some cases. The study was conducted […]
  • Lifestyle changes could delay memory problems in old age, depending on our genes April 2, 2020
    Researchers from King's College London have shown that how we respond to changes in nutrients at a molecular level plays an important role in the aging process, and this is directed by some key genetic mechanisms.
  • Study of rare genetic disorder that effects the eyes April 3, 2020
    Small gauge vitrectomy for vitreous amyloidosis and subsequent management of secondary glaucoma in patients with hereditary transthyretin amyloidosis.
  • Tissue dynamics provide clues to human disease April 3, 2020
    Scientists in EMBL Barcelona's Ebisuya group, with collaborators from RIKEN, Kyoto University, and Meijo Hospital in Nagoya, Japan, have studied oscillating patterns of gene expression, coordinated across time and space within a tissue grown in vitro, to explore the molecular causes of a rare human hereditary disease known as spondylocostal dysostosis. Their results are published […]
  • Coronavirus: Virological findings from patients treated in a Munich hospital April 3, 2020
    In early February, research teams from Charité - Universitätsmedizin Berlin, München Klinik Schwabing and the Bundeswehr Institute of Microbiology published initial findings describing the efficient transmission of SARS-CoV-2. The researchers' detailed report on the clinical course and treatment of Germany's first group of COVID-19 patients has now been published in Nature*. Criteria may now be […]
  • Case study: Treating COVID-19 in a patient with multiple myeloma April 3, 2020
    A case study of a patient in Wuhan, China, suggests that the immunosuppressant tocilizumab may be an effective COVID-19 treatment for very ill patients who also have multiple myeloma and other blood cancers. The report, published in Blood Advances, also suggests that blood cancer patients may have atypical COVID-19 symptoms.
  • Indigenous American ancestry may be associated with HER2-positive breast cancer April 3, 2020
    An increased proportion of Indigenous American (IA) ancestry was associated with a greater incidence of HER2-positive breast cancer, according to a study published in Cancer Research, a journal of the American Association for Cancer Research.